CDP-Choline (Citicoline) Research Overview (also known as Citicoline, Cytidine Diphosphocholine, Cytidine 5-diphosphocholine)
CDP-choline, commonly called citicoline, is a naturally occurring intermediate in the synthesis of phosphatidylcholine and a source of both choline and cytidine. Oral citicoline has been studied for attention, memory, cognitive decline, ischemic stroke recovery, traumatic brain injury, and retinal or optic-nerve disorders, although evidence varies substantially by indication and formulation.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is CDP-Choline (Citicoline)?
CDP-choline, or cytidine diphosphocholine, is a water-soluble nucleotide derivative composed of cytidine, diphosphate, and choline. It is also known as citicoline and is an endogenous intermediate in the Kennedy pathway, the principal biochemical route for synthesizing phosphatidylcholine. Phosphatidylcholine is a major structural phospholipid in neuronal and other cellular membranes, and it contributes to membrane integrity, vesicle formation, myelin maintenance, and lipoprotein metabolism. Citicoline is available as an oral supplement and, in some countries, as a pharmaceutical product administered orally, intravenously, or intramuscularly.
After oral administration, citicoline is extensively hydrolyzed during absorption into choline and cytidine-related compounds, including uridine in some tissues, and these components are subsequently taken up and recombined in cells. This dual-substrate profile distinguishes citicoline from choline salts and from isolated cytidine or uridine supplements. Research has examined citicoline as a potential support for cholinergic neurotransmission, phospholipid synthesis, mitochondrial and membrane function, dopamine signaling, and recovery from neural injury. It is not an established treatment for dementia, stroke, glaucoma, attention disorders, or any other disease, and clinical results have been mixed, particularly in acute stroke trials.
Research Indications
Cognitive Function
Post-stroke cognitive impairment
Clinical studies have examined prolonged oral citicoline administration for cognitive impairment following cerebrovascular events, with some trials reporting improvements on cognitive measures.
Memory and attention
Human research in older adults and individuals with memory complaints has investigated citicoline for attention, memory performance, and processing speed; results vary by population and study design.
Cerebrovascular Research
Acute ischemic stroke
Citicoline has been evaluated as an adjunct in acute ischemic stroke trials. Large studies have produced mixed findings and it is not a replacement for time-sensitive emergency stroke care.
Neuronal membrane metabolism
As a precursor to phosphatidylcholine, citicoline is studied for effects on phospholipid synthesis, membrane repair pathways, and choline availability.
Mood and Motivation
Mental energy and motivation
Anecdotal use and limited exploratory research describe possible effects on mental energy and motivation, but robust controlled evidence for mood outcomes remains limited.
Dopaminergic signaling
Preclinical work suggests citicoline may influence dopamine-related pathways. The clinical significance of these findings in healthy adults is uncertain.
Visual and Neurological Function
Glaucoma and optic nerve research
Small studies have explored citicoline as an adjunct in glaucoma and optic nerve conditions, often using non-oral formulations. Evidence is insufficient for self-treatment.
Traumatic brain injury
Citicoline has been investigated in neurological injury contexts, but its role in traumatic brain injury recovery remains unsettled and requires clinician-directed care.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General cognitive support | 250–500 mg | Once daily | Oral |
| Attention and memory studies | 500–1,000 mg | Once daily or divided | Oral |
| Clinical cognitive research | 1,000–2,000 mg | Divided daily | Oral |
| Longer-term protocols | 500–2,000 mg | Daily for weeks to months | Oral |
Timing
Citicoline is commonly taken in the morning or early afternoon, with or without food. Individuals who experience activation, headache, or sleep disruption may prefer a lower starting amount and avoidance of late-day dosing.
Peptide Interactions
Often paired for alertness and attention. The combination may feel more stimulating than either compound alone.
Both are choline donors. Combining them may be redundant and can increase the likelihood of cholinergic effects such as headache, nausea, or muscle tension.
Additional supplemental choline is generally unnecessary unless directed by a clinician; monitor total choline exposure and tolerability.
Citicoline is commonly used alongside racetams in nootropic communities, though controlled evidence for the combination is limited.
Citicoline may influence dopaminergic pathways and could alter responses to levodopa. Use only with prescribing-clinician oversight.
Donepezil, rivastigmine, and similar medicines affect cholinergic signaling; clinician review is appropriate before adding citicoline.
Reported Research Timeline
01Days 1–3 (reported in cited studies): some users notice no acute change; others report subtle alertness, focus, headache, or gastrointestinal effects.
02Week 1 (reported in cited studies): tolerability and any effects on daytime mental energy or concentration are typically easier to assess with consistent dosing.
03Weeks 2–4 (reported in cited studies): research-oriented cognitive assessments generally require repeated testing over weeks rather than judging effects from a single dose.
04Weeks 4–8 (reported in cited studies): if a meaningful benefit is present, it should be evaluated against sleep, stress, caffeine intake, and practice effects on cognitive tasks.
05Months 2–3 (reported in cited studies): longer clinical protocols have evaluated ongoing use, particularly in neurological populations; benefits should not be assumed to increase with dose.
06Ongoing (reported in cited studies): periodically reassess whether the compound provides a clear, reproducible benefit and discontinue or seek advice if adverse effects occur.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Reported adverse effects are usually mild and may include headache, insomnia, restlessness, nausea, diarrhea, or changes in appetite.
Begin with a lower oral amount, especially when also using caffeine, stimulant medications, or other choline-containing supplements.
Avoid using citicoline to self-manage symptoms of stroke, head injury, dementia, glaucoma, or other neurological disease.
Consult a clinician before use if pregnant, breastfeeding, managing a chronic medical condition, or taking prescription neurological or psychiatric medicines.
People with bipolar disorder, significant anxiety, or insomnia should use caution because activating effects may worsen symptoms in susceptible individuals.
Seek Medical Attention If:
You develop signs of a severe allergic reaction, including facial or throat swelling, widespread hives, wheezing, or difficulty breathing.
You experience severe or persistent headache, fainting, confusion, marked agitation, or a new severe mood change.
You have chest pain, a sustained rapid or irregular heartbeat, or severe vomiting after use.
You develop sudden weakness, facial droop, speech difficulty, vision loss, or other possible stroke symptoms; call emergency services immediately.
Quality Indicators
Verified Marker
Identity-confirmed citicoline
Look for CDP-choline or citicoline clearly identified on the label, with the amount specified per capsule or serving.
Verified Marker
Recent batch-specific COA
A certificate of analysis should identify the lot number and report identity and assay testing for the finished ingredient or batch.
Verified Marker
Independent contaminant testing
Prefer products with third-party testing for heavy metals and microbiological contaminants, particularly for frequent long-term oral use.
Acceptable Range
Capsule and dose transparency
Capsules or tablets should state the exact milligrams of citicoline per unit and list all excipients; avoid relying on proprietary blends.
Quality Concern
No accessible purity documentation
Avoid products that do not provide lot traceability, HPLC or equivalent purity information, or credible testing documentation when requested.
Research Citations
- Citicoline: pharmacological and clinical review, 2016 update
Secades, J. J., 2016, CNS Drugs - A randomized efficacy trial of citicoline in patients with acute ischemic stroke
Clark, W. M., Williams, B. J., Selzer, K. A., et al., 1997, Stroke - Oral citicoline in acute ischemic stroke: an international, randomized, multicenter, placebo-controlled study
Dávalos, A., Castillo, J., Alvarez-Sabín, J., et al., 2002, Stroke - Long-term treatment with citicoline may improve poststroke vascular cognitive impairment
Alvarez-Sabín, J., Román, G. C., 2013, Cerebrovascular Diseases
Research Focus
acetylcholine, choline, cytidine, uridine, cognitive function, neuroprotection, dopamine
Frequently Asked Questions
What should researchers watch for with CDP-Choline (Citicoline)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with CDP-Choline (Citicoline)?
Days 1–3 (reported in cited studies): some users notice no acute change; others report subtle alertness, focus, headache, or gastrointestinal effects.
How is CDP-Choline (Citicoline) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →